Koninklijke Philips N.V. (PHIA)-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Koninklijke Philips N.V. (PHIA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8012261
◆発行会社(調査会社):GlobalData
◆発行日:2017年12月14日
◆ページ数:59
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:オランダ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Koninklijke Philips N.V. (Philips) is a diversified technology company which focuses on improving people’s health and enabling better outcomes across the health continuum from healthy living and prevention, to diagnosis, treatment and home care. The company develops and manufactures medical systems, consumer electronics and lighting products. It offers patient care & clinical informatics, imaging systems, healthcare transformation services and home healthcare solutions. The company provides health & wellness, personal care and domestic appliances. Philips offers consumer luminaires, lumileds, professional lighting solutions, light sources & electronics and automotive lighting. The company also focuses on offering green products such as dimming backlights, and image processing intelligence. It has operational presence in both mature and growth geographies. The company caters to Healthcare, Consumer Life Style, and Lighting industries. Philips is headquartered in Amsterdam, the Netherlands.

Koninklijke Philips N.V. (PHIA) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Koninklijke Philips N.V., Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Koninklijke Philips N.V., Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Koninklijke Philips N.V., Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Koninklijke Philips N.V., Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
Koninklijke Philips N.V., Medical Devices Deals, 2011 to YTD 2017 10
Koninklijke Philips N.V., Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Koninklijke Philips N.V., Pharmaceuticals & Healthcare, Deal Details 13
Venture Financing 13
Biocartis Raises US$40.5 Million In Series E Financing 13
Biocartis Raises US$44.7 Million In Series D Financing 15
Biocartis Secures US$96 Million In Series C Financing Round 17
Partnerships 19
Royal Philips and Memorial Sloan Kettering Cancer Center Enter into Research Agreement 19
Koninklijke Philips Enters into Agreement with Illumina 20
Ion Beam Applications Enters into Agreement with Philips Healthcare 21
Royal Philips Enters into Agreement with Universitaire Ziekenhuizen Leuven 22
Ion Beam Applications Enters into Co-Development Agreement with Royal Philips 23
Teva Pharma Industries to Form Joint Venture with Philips Medical Systems 24
Lumalier Enters Into Distribution Agreement With Philips Healthcare 25
IBA Group Enters Into An Agreement With Royal Philips Electronics 26
Debt Offering 27
Royal Philips Prices Public Offering of Notes Due 2019 for USD596.6 Million 27
Royal Philips Prices Public Offering of Notes Due 2023 for USD596.6 Million 28
Acquisition 29
Philips to Acquire Unisensor, Analytical Instrument Provider 29
Zambon Acquires Profile Pharma from Philips 30
Volcano Completes Acquisition Of Crux Biomedical, Developer Of Implantable Filter, For Up To US$42.1 Million 31
Koninklijke Philips Electronics Plans For Acquisition In Home Healthcare Market 33
Koninklijke Philips N.V. – Key Competitors 34
Koninklijke Philips N.V. – Key Employees 35
Koninklijke Philips N.V. – Locations And Subsidiaries 36
Head Office 36
Other Locations & Subsidiaries 36
Joint Venture 38
Recent Developments 39
Strategy And Business Planning 39
Aug 24, 2017: Governor Haslam, Commissioner Rolfe Announce Philips to Establish Business Center of Expertise in Middle Tennessee 39
Financial Announcements 40
Oct 23, 2017: Philips’ Third Quarter Results 2017 40
Jul 24, 2017: Philips’ Second Quarter Results 2017 42
Corporate Communications 45
Oct 20, 2017: Extraordinary General Meeting of Shareholders appoints Marnix van Ginneken to Philips’ Board of Management 45
Sep 18, 2017: Philips Steps Up Commitment to Ensuring Healthy Lives for All During United Nations General Assembly Week 46
Jul 20, 2017: Chief Business Leader of Philips’ Personal Health businesses Pieter Nota to leave company 47
Mar 21, 2016: Philips aims to address billions of people globally to encourage healthy oral habits 48
Government and Public Interest 49
Nov 23, 2017: Philips-led research consortium awarded EUR 6.3 million EU grant to develop integrated approaches for personalized cancer treatment 49
Apr 21, 2017: New study with Philips Trilogy reveals payers and hospitals can save millions in readmission costs, hospitalization rates for COPD patients 50
May 31, 2016: VA Awards Philips Research Grant for Exploring How Personalized Location-aware Assisted Technology Can Improve Quality of Life for People with Mild Cognitive Impairment 52
Mar 03, 2016: Philips survey reveals clinical improvements in population health efforts are key priorities driving health IT investments 53
Product News 54
Jun 09, 2017: Phillips Company Issues Voluntary Worldwide Recall of All Topical Products Due to Concerns of Manufacturing Practices 54
Other Significant Developments 55
Nov 02, 2017: Philips provides update on the company strategy and performance at Capital Markets Day in New York 55
Sep 14, 2017: Philips reaffirms commitment to patient safety by joining coalition to advance quality and safety in healthcare 56
Mar 18, 2016: Philips launches “World’s Sleepiest Website” to help restless sleepers maximize their slumber 57
Mar 01, 2016: Philips introduces Aging Well Services, bringing personalized connected health offerings to help seniors stay healthy and safe 58
Appendix 59
Methodology 59
About GlobalData 59
Contact Us 59
Disclaimer 59

List of Tables
Koninklijke Philips N.V., Pharmaceuticals & Healthcare, Key Facts, 2016 2
Koninklijke Philips N.V., Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Koninklijke Philips N.V., Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Koninklijke Philips N.V., Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Koninklijke Philips N.V., Deals By Therapy Area, 2011 to YTD 2017 9
Koninklijke Philips N.V., Medical Devices Deals, 2011 to YTD 2017 10
Koninklijke Philips N.V., Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Biocartis Raises US$40.5 Million In Series E Financing 13
Biocartis Raises US$44.7 Million In Series D Financing 15
Biocartis Secures US$96 Million In Series C Financing Round 17
Royal Philips and Memorial Sloan Kettering Cancer Center Enter into Research Agreement 19
Koninklijke Philips Enters into Agreement with Illumina 20
Ion Beam Applications Enters into Agreement with Philips Healthcare 21
Royal Philips Enters into Agreement with Universitaire Ziekenhuizen Leuven 22
Ion Beam Applications Enters into Co-Development Agreement with Royal Philips 23
Teva Pharma Industries to Form Joint Venture with Philips Medical Systems 24
Lumalier Enters Into Distribution Agreement With Philips Healthcare 25
IBA Group Enters Into An Agreement With Royal Philips Electronics 26
Royal Philips Prices Public Offering of Notes Due 2019 for USD596.6 Million 27
Royal Philips Prices Public Offering of Notes Due 2023 for USD596.6 Million 28
Philips to Acquire Unisensor, Analytical Instrument Provider 29
Zambon Acquires Profile Pharma from Philips 30
Volcano Completes Acquisition Of Crux Biomedical, Developer Of Implantable Filter, For Up To US$42.1 Million 31
Koninklijke Philips Electronics Plans For Acquisition In Home Healthcare Market 33
Koninklijke Philips N.V., Key Competitors 34
Koninklijke Philips N.V., Key Employees 35
Koninklijke Philips N.V., Subsidiaries 36
Koninklijke Philips N.V., Joint Venture 38

★海外企業調査レポート[Koninklijke Philips N.V. (PHIA)-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Illumina, Inc.:企業のM&A・事業提携・投資動向
    Illumina, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Illumina, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestmen …
  • Staatsolie Maatschappij Suriname NV:企業の戦略的SWOT分析
    Staatsolie Maatschappij Suriname NV - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major …
  • Quidel Corp (QDEL):医療機器:M&Aディール及び事業提携情報
    Summary Quidel Corp (Quidel) develops, manufactures and markets rapid diagnostic testing solutions for the detection and diagnosis of critical diseases and other medical conditions. Its major products include immunoassays; molecular assays; virology products including traditional cell lines, specime …
  • YGM Trading Ltd.:戦略・SWOT・企業財務分析
    YGM Trading Ltd. - Strategy, SWOT and Corporate Finance Report Summary YGM Trading Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Aratana Therapeutics Inc (PETX):企業の財務・戦略的SWOT分析
    Summary Aratana Therapeutics Inc (Aratana) is a provider of pet care solutions. The company develops, commercializing and markets biopharmaceutical products for medical condition in cats and dogs. Its pipeline portfolio consists of small molecule pharmaceuticals and large molecule biologics that aim …
  • Tenaga Nasional Berhad (TENAGA)-エネルギー分野:企業M&A・提携分析
    Summary Tenaga Nasional Berhad (TNB) is an electricity utility that generates, transmits, distributes and supplies power. It develops, operates and maintains a portfolio of power generating units. The company produces electricity from crude oil, natural gas, hydro, coal and gas sources. TNB also sup …
  • EPAM Systems Inc (EPAM):企業の財務・戦略的SWOT分析
    EPAM Systems Inc (EPAM) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • Midatech Pharma Plc (MTPH)-医療機器分野:企業M&A・提携分析
    Summary Midatech Pharma Plc (Midatech) is a pharmaceutical company that develops and commercialize oncology and other therapeutic products. The company’s products include gelclair, oravig, soltamox, zuplenz, ferralet 90 and aquoral. It conducts research and development programs in areas of oncology, …
  • Sernova Corp (SVA):製品パイプライン分析
    Summary Sernova Corp (Sernova) is a clinical stage regenerative medicines company which develops and commercializes medical device and combination products for the treatment of chronic diseases. The company is developing Cell Pouch System, an implantable medical device, which offers a natural organ- …
  • IRWIN Industrial Tool Co:企業の戦略的SWOT分析
    IRWIN Industrial Tool Co - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products a …
  • Entergy Corporation (ETR):企業の財務・戦略的SWOT分析
    Entergy Corporation (ETR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Keppel Corporation Limited:企業の戦略・SWOT・財務分析
    Keppel Corporation Limited - Strategy, SWOT and Corporate Finance Report Summary Keppel Corporation Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • Traverse Biosciences Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Traverse Biosciences Inc (Traverse Biosciences) is an privately held bioscience company that commercializes drug candidates for the treatment of inflammatory diseases and age-related conditions affecting humans and companion animals. The company provides lead candidate TRB-N0224 which is dev …
  • John Menzies Plc
    John Menzies Plc - Strategy, SWOT and Corporate Finance Report Summary John Menzies Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Keio Corporation:企業の戦略・SWOT・財務分析
    Keio Corporation - Strategy, SWOT and Corporate Finance Report Summary Keio Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • PromptCare Inc-製薬・医療分野:企業M&A・提携分析
    Summary PromptCare Inc (PromptCare) is a healthcare center that respiratory products and home infusion services. The center provides respiratory services such as clinical support programs, patient-focused technology and testimonials. It provides home infusion therapies for patients of all ages with …
  • New Zealand Oil & Gas Ltd (NZO):石油・ガス:M&Aディール及び事業提携情報
    Summary New Zealand Oil & Gas Ltd (NZOG) is an oil and gas that offers oil and gas exploration, development and production. The company acquires, explores, and develops crude oil and natural gas properties. Its producing assets include Maari and Manaia fields, Kupe gas and light oil field, and Sampa …
  • Showa Aircraft Industry Co., Ltd.
    Showa Aircraft Industry Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Showa Aircraft Industry Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, pro …
  • Green Plains Inc.:企業の戦略・SWOT・財務情報
    Green Plains Inc. - Strategy, SWOT and Corporate Finance Report Summary Green Plains Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Guangzhou Improve Medical Instruments Co Ltd (300030):医療機器:M&Aディール及び事業提携情報
    Summary Guangzhou Improve Medical Instruments Co Ltd (Improve Medical) is a medical devices company that offers medical products, technologies, and services for clinical laboratory and clinical nursing. The company’s products include Improvacuter evacuated blood collection systems, Impromini capilla …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆